AP NEWS

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NSANY, APHA, CURO and IMMU

January 28, 2019

NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Nissan Motor Co., Ltd. (OTCMKTS: NSANY) Class Period: December 10, 2013 to November 16, 2018 Lead Plaintiff Deadline: February 8, 2019

During the class period, Nissan Motor Co., Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) for more than a decade, Nissan had been materially understating its costs--and thus overstating profits--by paying a material portion of Ghosn’s executive compensation in the form of billions of Yen of deferred compensation that the Company was concealing from its public financial reports; (2) in so doing, Nissan was concealing from investors significant defects in its corporate governance; (3) Nissan’s overpayment of defendant Ghosn had caused it to exceed its shareholder-approved executive pay cap, thus threatening its continued stock listing; (4) Nissan lacked effective internal and reporting controls; and (5) as a result, defendants’ statements about Nissan’s business metrics, operations, and financial prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the NSANY lawsuit: http://www.kleinstocklaw.com/pslra-1/nissan-motor-co-ltd-loss-submission-form?wire=3

Aphria Inc. (NYSE: APHA) Class Period: July 17, 2018 to December 4, 2018 Lead Plaintiff Deadline: February 4, 2019

According to the complaint, Aphria Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Latin American assets acquired by the Company lacked adequate licenses to operate and were overvalued; (2) the acquisition of the Latin American assets would enrich the Company’s CEO and other insiders at the expense of shareholders; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the APHA lawsuit: http://www.kleinstocklaw.com/pslra-1/aphria-inc-loss-submission-form?wire=3

CURO Group Holdings Corp. (NYSE: CURO) Class Period: July 31, 2018 to October 24, 2018 Lead Plaintiff Deadline: February 4, 2019

The complaint alleges that throughout the class period Defendants materially misrepresented to investors the deleterious effect that the up-front loan loss provisioning in connection with a transition of its Canadian inventory to Open-Ended loans was having on the Company’s financial performance and 2018 full-year Company guidance. Because CURO’s Open-End Loans had a materially lower lending yield than the Single-Pay Products, and the portfolio of Open-End Loans was still immature and unseasoned, the up-front loan loss provisioning for these loans was far greater than publicly revealed (and the yield far lower). This caused the Company to materially overstate its 2018 projected financial results, including CURO’s adjusted EBITDA, net revenue and operating earnings.

Get additional information about the CURO lawsuit: http://www.kleinstocklaw.com/pslra-1/curo-group-holdings-corp-loss-submission-form?wire=3

Immunomedics, Inc. (NASDAQ: IMMU) Class Period: August 23, 2018 to December 20, 2018 Lead Plaintiff Deadline: February 25, 2019

The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.

Get additional information about the IMMU lawsuit: http://www.kleinstocklaw.com/pslra-1/immunomedics-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:J. Klein, Esq.Empire State Building350 Fifth Avenue59th FloorNew York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899Fax: (347) 558-9665 www.kleinstocklaw.com

AP RADIO
Update hourly